4.7 Article

Neuropsychological Outcome of Children Treated for Standard Risk Medulloblastoma in the PNET4 European Randomized Controlled Trial of Hyperfractionated Versus Standard Radiation Therapy and Maintenance Chemotherapy

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ijrobp.2015.04.023

关键词

-

资金

  1. Brain Tumour Charity
  2. Children's Cancer and Leukaemia Group
  3. German Ministry of Health and Education [BMBF 01GI9958/5]
  4. European Union Seventh Framework Programme (FP7) under project European Network for Cancer Research in Children and Adolescents (ENCCA) [261743]
  5. German Children's Cancer Foundation (Deutsche Kinderkrebsstiftung), Fordergemeinschaft Kinderkrebszentrum Hamburg e.V.
  6. French Ministry of Health
  7. French National Cancer Institute
  8. Swedish Childhood Cancer Foundation
  9. Wessex Medical Research
  10. Cancer Research UK
  11. Piam Brown Charitable Fund Southampton

向作者/读者索取更多资源

Purpose: In the European HIT-SIOP PNET4 randomized controlled trial, children with standard risk medulloblastoma were allocated to hyperfractionated radiation therapy (HFRT arm, including a partially focused boost) or standard radiation therapy (STRT arm), followed, in both arms, by maintenance chemotherapy. Event-free survival was similar in both arms. Previous work showed that the HFRT arm was associated with worse growth and better questionnaire-based executive function, especially in children < 8 years of age at diagnosis. Therefore, the aim of this study was to compare performance-based cognitive outcomes between treatment arms. Methods and Materials: Neuropsychological data were collected prospectively in 137 patients. Using the Wechsler Intelligence Scales, Kaufman Assessment Battery for Children, and Raven's Progressive Matrices, we estimated full-scale intelligence quotient (FSIQ) and, when available, verbal IQ (VIQ), performance IQ (PIQ), working memory index (WMI), and processing speed index (PSI). Results: Among the 137 participants (HFRT arm n=71, STRT arm n=66, 63.5% males), mean (+/- SD) ages at diagnosis and assessment respectively were 9.3 (+/- 3.2) years of age (40.8% < 8 years of age at diagnosis) and 14.6 (+/- 4.3) years of age. Mean (+/- SD) FSIQ was 88 (+/- 19), and mean intergroup difference was 3.88 (95% confidence interval: -2.66 to 10.42, P = .24). No significant differences were found in children > 8 years of age at diagnosis. In children < 8 years of age at diagnosis, a marginally significant trend toward higher VIQ was found in those treated in the HFRT arm; a similar trend was found for PSI but not for PIQ, WMI, or FSIQ (mean intergroup differences were: 12.02 for VIQ [95% CI: 2.37-21.67; P=.02]; 3.77 for PIQ [95% CI: -5.19 to 12.74; P>.10]; 5.20 for WMI [95% CI: -2.07 to 12.47; P>.10]; 10.90 for PSI [95% CI: -1.54 to 23.36; P=.08]; and 5.28 for FSIQ [95% CI: -4.23 to 14.79; P>.10]). Conclusions: HFRT was associated with marginally higher VIQ in children < 8 years of age at diagnosis, consistent with a previous report using questionnaire- based data. However, overall cognitive ability was not significantly different. (C) 2015 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据